Unparalleled expertise in clinical trials.
The increasing cost and complexity of clinical trials demand an innovative partner to help guide a trial through every phase, every day. Versiti has 75 years of expertise in blood health innovation, making new ideas and innovative approaches accessible to our clinical trial partners. Explore our insights below.
Empowering Cell & Gene therapy Advancements - Meeting on the Mesa Presentation
View Versiti Chief Marketing Officer Gitesh Dubal's presentation discussing Versiti's capabilities, strategic acquisitions and real-word case studies driving streamlined clinical trials.
Customized Starting Materials for Manufacturing Client Highlight
Learn more about how Versiti’s consultative approach and partnership with a client established a process for a recallable and usable contributor bank to provide quality starting materials for manufacturing in this case highlight.
Selecting the Right Biomaterial Product: Regulatory Considerations and Terminology in Leukopak Collections
Navigating the regulatory and compliance guidelines for source materials like leukopaks or other human blood products for the emerging cell therapy market involves having a clear understanding of your research goals. Download Versiti’s whitepaper discussing regulatory considerations in selecting the right biomaterial product.
Compliance and Transparency of Clinical Trial Data Reporting
The increasing cost and complexity of clinical trials demand an innovative partner to help guide a trial through every phase, every day. Download our white paper to see how Versiti Clinical Trials can help.
Filling the Leukopak Gap
With significant growth in the cellular therapy market projected over the next 4-6 years, several limiting factors, including the high cost of leukapheresis and stringent donor recruitment criteria for leukopak collections pose a unique set of challenges for companies without significant experience in the space.
Virtual Clinical Trials: Regulatory Concerns
Digital elements of clinical trials like electronic medical records, wearable devices, and digital sensors and apps have all previously been employed as supplements to traditional data collection. Before COVID-19, the demand for the kind of technology needed to support virtual clinical trials was much lower. Digital alternatives to in-person appointments, testing, and check-ins experienced a sudden demand increase due to the pandemic and have caused digital clinical trials to accelerate at an unprecedented speed.
Reduction of Pre- and Post-Analytical Errors in the Integrated CRO Model
Did you know that in clinical settings, diagnostic testing errors are the most prevalent type of malpractice claim? Advances in automation, sample collection, transport and data reporting have reduced the frequency of these errors to less than 10%. But how do you reduce the remaining 90% of errors that occur outside the clinical laboratory?
Fundamental Trust: Not for Sale
New quality concerns from the U.S. government lay bare the risks of choosing a for-profit IRB. Can for-profit IRBs serve as a human subject safety net, responsible for protecting the hundreds of thousands of people who enroll in clinical trials each year? Non-profit IRBs, like Salus, represent a compelling alternative for businesses in search of a solution.